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Background: Metabolic abnormalities have a cumulative effect on development of diabetes, but only central
obesity has been defined as the essential criterion of metabolic syndrome (MetS) by the International Diabetes
Federation. We hypothesized that central obesity contributes to a higher risk of new-onset diabetes than other
metabolic abnormalities in the hypertensive families.
Methods: Non-diabetic Chinese were enrolled and MetS components were assessed to establish baseline data in a
hypertensive family-based cohort study. Based on medical records and glucose tolerance test (OGTT), the cumulative
incidence of diabetes was analyzed in this five-year study by Cox regression models. Contribution of central obesity to
development of new-onset diabetes was assessed in subjects with the same number of positive MetS components.
Results: Among the total of 595 subjects who completed the assessment, 125 (21.0%) developed diabetes. Incidence of
diabetes increased in direct proportion to the number of positive MetS components (P< 0.001). Although subjects with
central obesity had a higher incidence of diabetes than those without (55.7 vs. 30.0 events/1000 person-years, P< 0.001),
the difference became non-significant after adjusting of the number of positive MetS components (hazard ratio= 0.72,
95%CI: 0.45-1.13). Furthermore, in all participants with three positive MetS components, there was no difference in the
incidence of diabetes between subjects with and without central obesity (hazard ratio= 1.04, 95%CI: 0.50-2.16).
Conclusion: In Chinese hypertensive families, the incidence of diabetes in subjects without central obesity was similar to
that in subjects with central obesity when they also had the same number of positive MetS components. We suggest that
central obesity is very important, but not the essential component of the metabolic syndrome for predicting of new-onset
diabetes. (Trial registration: NCT00260910, ClinicalTrials.gov).
Keywords: Metabolic syndrome, Incidence, New-onset diabetes, Obesity* Correspondence: whhsheu@vghtc.gov.tw
1Division of Endocrinology and Metabolism, Department of Internal
Medicine, Taichung Veterans General Hospital, Taichung, 407, Taiwan
3School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan
Full list of author information is available at the end of the article
© 2012 Lee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lee et al. Cardiovascular Diabetology 2012, 11:43 Page 2 of 8
http://www.cardiab.com/content/11/1/43Background
It is well known that insulin resistance is associated with
hypertension [1]. Within hypertensive families, interest-
ingly, subjects without hypertension also have high insu-
lin resistance, which is similar in degree to that of
subjects with present hypertension [2]. On the other
hand, obesity imposes an additional impact on insulin
resistance in the members of a hypertensive family,
regardless of whether they have hypertension or not
[3,4]. Although high insulin resistance has been observed
among hypertensive family members, it was reported
that the prevalence of diabetes was not significantly
higher in comparison to those without a family history
of hypertension [5].
Metabolic syndrome (MetS) is composed of a cluster
of cardiovascular risks [6]. A higher number of positive
MetS components is usually correlated with a higher risk
of developing cardiovascular disease and diabetes [7].
Central obesity is considered a pivotal component in
MetS, and it is defined as the only indispensable compo-
nent of MetS based on the diagnostic criteria of the
International Diabetes Federation (IDF), [8-10]. It is
notable that subjects with central obesity often have
more metabolic disorders and thus are at greater risk of
developing diabetes than those without central obesity
[11]. Even in subjects without obesity, it has been
reported that a higher body mass index (BMI) tends to
correlate with a higher number of positive MetS compo-
nents [12,13]. However, it is debatable whether central
obesity is still indispensable among subjects with the
same number of positive MetS components, and whether
subjects without central obesity should not be diagnosed
as having MetS [9,14-16]. Therefore, in this study, we
wanted to test the hypothesis that central obesity would
be associated with more cases of new-onset diabetes in
subjects within hypertensive families characterized by
high insulin resistance.
Methods
This cohort study was a five-year epidemiological follow-
up study conducted in Taiwan, which was an extension of
the previously published Stanford Asia-Pacific Program for
Hypertension and Insulin Resistance (SAPPHIRe) [17].
Briefly, the study was family-based and enrolled concord-
ant sib pairs (both hypertensive sibs) and discordant sibs
(one with hypertension and one without hypertension).
The study subjects were aged between 35 and 60 years,
but those who were pregnant, or had chronic kidney
disease (serum creatinine> 133 μmol/L), cancer or
other severe chronic diseases such as liver cirrhosis
were excluded from the study [18]. This follow-up
study was only conducted at four teaching hospitals in
Taiwan. All subjects were Chinese and were excluded
if they had diabetes at baseline. The study wasapproved by the Institutional Review Boards at all
participating sites. Written informed consent was obtained
from all subjects (Trial registration: NCT00260910,
ClinicalTrials.gov).
The anthropometric assessments were performed in the
morning after an overnight fast. The measurements of
body weight (DETECTO, Cardinal Scale Manufacturing
Co., Webb City, MO, USA) and body height (Pharmacia
Taiwan Inc., Taipei, Taiwan) were performed after partici-
pants removed their shoes or any heavy clothing. Waist
circumference (kp-1508, King Life, Taipei, Taiwan) was
measured at the level of the umbilicus after expiration
while the participant breathed quietly and regularly. Blood
pressure was detected using the DINAMAPTM Vital Signs
Monitor (Model 1846 SX/P) after subjects had been sitting
at rest for 10 min. The average of the second and the third
readings from three separate readings with intervals of
1 min was recorded. Overnight fasting blood samples were
collected for measurements of glucose, insulin and
lipoprotein profiles after obtaining the anthropometric
measurements. The homeostasis model assessment for
insulin resistance (HOMA-IR) index was calculated using
the formula of [fasting insulin (μU/mL) * fasting glucose
(mmol/L)]/22.5 [17]. A standard 75 g oral glucose toler-
ance test (OGTT) was performed for measurement of
post-challenge plasma glucose level at 120 minutes (2 hr
pc glucose) at baseline and at the end of 5-year follow-up,
except when diabetes had been diagnosed in clinical
practice. The medical records about diabetes were traced
during the study.
Based on the Third Report of the National Cholesterol
Education Program (NCEP), MetS is defined as the pres-
ence of three or more of the following components [6]: (1)
waist circumference≥ 90 cm in men or≥ 80 cm in women
[10,19], (2) triglycerides≥ 150 mg/dl (1.7 mmol/L), (3)
High-density lipoprotein (HDL) cholesterol< 40 mg/dl
(1.0 mmol/L) in men or< 50 mg/dl (1.3 mmol/L) in
women, (4) blood pressure≥ 130/85 mmHg or using anti-
hypertensive medications and (5) fasting glucose≥ 100
mg/dl (5.6 mmol/L) [10]. The diagnosis of diabetes in the
current study was based on the presence of one or more
of the following criteria: (1) fasting glucose≥ 126 mg/dl
(7.0 mmol/L), (2) OGTT≥ 200 mg/dl (11.1 mmol/L), or
(3) use of anti-diabetic agents.
Statistical analyses
All descriptive data were presented as mean ± standard
deviation or number with percentage of subjects. All
subjects were classified as having central obesity if waist
circumference ≥ 90 cm in men or ≥ 80 cm in women.
Regression analyses based on the generalized estimating
equation (GEE) approach were conducted to assess the
significance of the differences among groups. The GEE
approach was applied to account for corrections among
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models, which accounted for within-family correlations,
were used to analyze the associations of each MetS
component with incidence of diabetes. All the statistical
analyses were performed using SAS software version
9.1.3 (SAS, Cary, NC, USA).
Results
Of the total number of 1220 study subjects enrolled, 625
subjects did not complete the assessments in the follow-up
phase. Data from the 595 subjects with complete informa-
tion about MetS and diabetes were collected and analyzed
(Figure 1). There were no significant differences in baseline
characteristics, including gender, age, smoking status, BMI,
blood pressure, glucose, lipid profiles and HOMA-IR,
between the subjects who were lost during follow-up and
those whose complete data were collected. All study
subjects were classified into one of five groups based on
the number of positive MetS components: 0, 1, 2, 3, and
4/5 factors. The characteristics of these five groups are
shown in Table 1. At the end of the study, the number of
subjects diagnosed with diabetes were 4 (5.2%), 19 (12.0%),
34 (21.9%), 36 (27.1%) and 32 (44.4%) in groups 1 to 5,
respectively. As expected, we found a higher number of
positive MetS components correlated with a higher inci-
dence of diabetes (Figure 2).
In order to assess the effect of central obesity on
development of diabetes, all study subjects were classified1923 subjects were registered 
in phase 1 in Taiwan 
1220 subjects were enrolled 
at baseline 
125 subjects developed diabetes 470 subjec
Figure 1 Flow diagram of enrollment of study subjects.into with central obesity group or without central obesity
group according to the criterion of waist circumference.
Subjects with central obesity had higher blood pressure,
higher triglycerides, lower HDL cholesterol and higher
glucose levels (all P values less than 0.001). A higher
incidence of diabetes was also noted in the with central
obesity group than in the without central obesity group
(55.7 vs. 30.0 cases/1000 person-years, P = 0.009)
(Table 2). Since obese subjects had a higher number of
positive MetS components (2.9 ± 1.0) than those with-
out obesity (1.3 ± 1.0) (Figure 3), the hazard ratio was
calculated after adjusting for the number of positive
MetS components, age, gender and smoking. We found
that there was no significant difference in development
of diabetes between subjects with central obesity and
those without central obesity (hazard ratio = 0.72, 95%
CI = 0.45-1.13, P = 0.151).
When analyses were limited to subjects with three
positive MetS components, there was no significant differ-
ence in baseline HOMA-IR between subjects with and
those without central obesity (Table 3). The incidence of
diabetes in subjects with central obesity was not signifi-
cantly different from the incidence in those without central
obesity (55.3 vs. 43.9 cases/1000 person-years, P = 0.792).
After adjusting for age, gender and smoking, there was still
no significant difference in incidence of diabetes between
subjects with and those without central obesity (hazard
ratio = 1.04, 95% CI= 0.50 - 2.16, P = 0.918).263 subjects with diabetes mellitus 
440 subjects without complete assessment of 
metabolic syndrome 
ts did not develop diabetes
625 subjects were lost to follow-up 
Table 1 The baseline characteristics of study subjects categorized by number of positive components in metabolic
syndrome
0 1 2 3 4/5 P#
No. of patients 77 158 155 133 72
Male gender, n (%) 28 (36.4%) 64 (40.5%) 69 (44.5%) 68 (51.1%)* 45 (62.5%)*** <0.001
Age (years) 45.6±7.5 47.2±8.4 47.8±8.8 49.9±9.1** 50.3±8.8** <0.001
Smoking (packs/day*year) 2.8±6.42 3.1±8.1 4.7±10.7 5.3±10.1* 9.4±13.5*** <0.001
Body Mass Index (kg/m2) 21.9±1.9 23.7±2.4*** 25.2±2.9*** 26.6±2.9*** 27.7±2.4*** <0.001
Waist circumference (cm) 74.7±6.1 78.5±7.8*** 83.1±9.7*** 88.6±9.2*** 92.0±6.8*** <0.001
Systolic BP (mmHg) 103±10 121±26*** 132±24*** 137±23*** 144±23*** <0.001
Diastolic BP (mmHg) 64±7 74±14*** 78±14*** 81±13*** 84±12*** <0.001
Fasting glucose (mmol/L) 4.7±0.4 4.8±0.4 4.9±0.4* 5.0±0.6*** 5.4±0.6*** <0.001
2hr pc glucose (mmol/L) 6.5±1.8 6.9±1.5 7.0±1.9* 7.5±1.7*** 8.4±1.8*** <0.001
Insulin (μU/mL) 4.2±1.9 5.7±3.1*** 7.3±4.6*** 8.5±4.6*** 11.5±5.7*** <0.001
HOMA-IR 0.9±0.4 1.3±0.7*** 1.6±1.1*** 1.9±1.1*** 2.8±1.5*** <0.001
Triglyceride (mmol/L) 0.8±0.3 1.0±0.4*** 1.3±0.6*** 1.6±0.9*** 2.4±1.1*** <0.001
HDL cholesterol (mmol/L) 1.5±0.3 1.2±0.3*** 1.1±0.3*** 1.0±0.2*** 0.9±0.2*** <0.001
Total cholesterol (mmol/L) 4.6±0.9 4.8±1.1 4.8±0.9 4.8±1.1 4.9±0.9 0.177
LDL cholesterol (mmol/L) 2.7±0.8 3.1±1.1 3.1±0.9 3.1±1.0 3.0±0.9 0.393
#: P value among the five group.
*: P<0.05, **: P<0.01 and ***: P<0.001 in comparison with the 0 group.
Abbreviations: 2hr pc glucose= postchallenge plasma glucose level at 120 min, BP= blood pressure, HDL= high-density lipoprotein, HOMA-IR= homeostasis model
assessment for insulin resistance and LDL= low-density lipoprotein.
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individual MetS components showed particular relevance
to subsequent risk of new-onset diabetes. In contrast,
hypertriglyceridemia and impaired fasting glucose were
the most important predictors for diabetes in the
subjects with central obesity (Table 4).
Discussion
In a hypertensive family cohort characterized by insulin
resistance [2-4], we found a cumulative effect of MetS



































*: P<0.05 and **: P<0.01 in comparison with
Figure 2 Incidence of diabetes among different numbers of positive cwas relatively similar to that reported in the West of
Scotland Coronary Prevention Study (WOSCOPS) [7]. In
a high insulin-resistance population, the effect of MetS
accumulation was also observed in subjects with
impaired fasting glucose [20]. Our most important find-
ing is that the risk of developing new-onset diabetes was
associated with the number of positive MetS compo-
nents, but not with central obesity. When analyses were
limited to those subjects with three MetS components,
neither insulin resistance (expressed by HOMA-IR) at
baseline, nor diabetes incidence during follow-up was2 3 4/5
01 
 the 0 group
omponents in metabolic syndrome.
Table 2 The baseline characteristics of study subjects






No. of patients 234 361
Male gender, n (%) 105 (44.9%) 169 (46.8%) 0.755
Age (years) 50.0±9.4 46.9±8.0 <0.001
Smoking (packs/day) 6.4±11.8 3.6±8.5 <0.001
Waist circumference (cm) 91.9±7.3 77.4±7.0 <0.001
Systolic BP (mmHg) 135±25 123±25 <0.001
Diastolic BP (mmHg) 79±14 75±14 <0.001
Fasting glucose (mmol/L) 5.1±0.6 4.9±0.5 <0.001
Triglyceride (mmol/L) 1.5±0.8 1.3±0.8 <0.001
HDL cholesterol (mmol/L) 1.1±0.3 1.2±0.3 <0.001




Abbreviations: BP= blood pressure, HDL= high-density lipoprotein, HOMA-IR=
homeostasis model assessment for insulin resistance.
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central obesity. Previous reports that subjects with
central obesity had a higher risk of developing diabetes
might be based on the evidence that these individuals
has a higher number of associated MetS components
[21,22]. In accord with our observations, results from the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
demonstrated that MetS was a better predictor of devel-
opment of diabetes than BMI in hypertensive subjects
[23]. Nevertheless, Yasuda T, et al. [24] found that central
obesity did not impose any additional influence on
carotid atherosclerosis among subjects with theFigure 3 The numbers of positive components in metabolic syndromesame number of positive MetS components in a cross-
sectional study. Non-obese subjects with metabolic
syndrome also had a similar risk of developing cardiovas-
cular disease compared with obese individuals in
prospective observations [25,26]. In fact, a joint interim
statement from several associated organizations has
suggested that MetS criteria need to be unified and waist
circumference might not be the prerequisite for the
criteria [27].
The proportion of new-onset diabetes among the
members of hypertensive families in the present study
was higher than that in the WOSCOPS and also than
that reported in a previous Chinese community survey
[7,28]. On the other hand, Shirakawa et al. [5] had
reported that a family history of hypertension was
associated with the presence of hypertension but not
diabetes in a previous cross-sectional study. According
to the high cumulative incidence of diabetes in our
prospective cohort, however, a family history of hyper-
tension does provide important information in predicting
development of diabetes. These findings might be due to
the hyperinsulinemia observed in hypertensive family [2].
High fasting insulin is associated with many metabolic
abnormities and can lead MetS to progress [29].
Similarly, in the present study, insulin resistance with
high fasting insulin levels had a positive association with
the number of MetS components and incidence of
diabetes. However, we did not further assess the possible
mechanisms connecting a family history of hypertension
and the incidence of diabetes. It has been reported that
circulating aldosterone might associate with insulin
resistance [30], and the autonomic imbalance is probably
related to diabetes [31].between subjects with central obesity and without central obesity.
Table 3 The baseline characteristics of study subjects






No. of patients 89 44
Male gender, n (%) 42 (47.2%) 26 (59.1%) 0.163
Age (years) 50.6±9.6 48.4±7.7 0.004
Smoking (packs/day) 5.5±10.3 4.9±9.6 0.616
Body Mass Index (kg/m2) 27.4±2.8 24.8±2.1 <0.001
Waist circumference (cm) 92.3±8.2 81.2±6.2 <0.001
Systolic BP (mmHg) 138±23 136±22 0.500
Diastolic BP (mmHg) 81±14 81±12 0.889
Fasting glucose (mmol/L) 5.0±0.6 5.1±0.6 0.200
2hr pc glucose (mmol/L) 7.3±1.8 7.9±1.4 0.112
Triglyceride (mmol/L) 1.4±0.8 2.1±0.7 <0.001
HDL cholesterol (mmol/L) 1.1±0.2 0.9±0.2 <0.001
Total cholesterol (mmol/L) 4.8±1.0 4.7±1.2 0.772
LDL cholesterol (mmol/L) 3.2±0.9 3.0±1.1 0.564




Abbreviations: 2hr pc glucose= post-challenge plasma glucose level at 120 minutes,
BP= blood pressure, HDL= high-density lipoprotein, HOMA-IR= homeostasis model
assessment for insulin resistance and LDL= low-density lipoprotein.
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mechanisms, and frequently coexist. Although the
predictive power of MetS seems not as strong as the
sum of all its components, the diagnosis of MetS is
important as a superimposed risk on traditional risk
factors. [20,32,33]. On the other hand, subjects without
obesity probably have several metabolic abnormalities
which can lead to an increased risk of diabetes [34,35].
In this regard, we should not ignore the potential risk in
subjects without central obesity. Furthermore, severalTable 4 Cox regression models for the effects of
metabolic syndrome on the incidence of diabetes in







HR 95% CI P HR 95% CI P
Hypertension 1.61 (0.86,3.00) 0.137 1.46 (0.71,3.00) 0.309
Low HDL cholesterol 1.69 (0.92,3.09) 0.090 1.11 (0.63,1.98) 0.714
Hypertriglyceridemia 1.17 (0.56,2.44) 0.682 2.34 (1.44,3.80) 0.001
Impaired fasting
glucose
1.83 (0.77,4.33) 0.168 3.00 (1.63,5.54) <0.001
Adjusted for age, gender, smoking and waist circumference.
Abbreviations: CI = confidence interval, HDL= high-density lipoprotein, HR =
hazard ratio.studies showed that impaired fasting glucose is a strong
predictor of development of diabetes [20,23,28]. In
addition to glucose, fasting triglyceride was the other
independent predictor of onset of diabetes in Chinese
subjects [28]. In particular, these finding is obvious in
the subjects with central obesity in our data (see Table 4).
In fact, lipotoxicity by deposition of triglycerides and free
fatty acids may be associated with insulin resistance and
beta-cell dysfunction [36,37]. Therefore, it is important
to closely monitor or treat subjects with high levels of
triglycerides and glucose because these two components
are clearly associated with development of diabetes,
especially in those with central obesity [37,38].
There were a few limitations in the present study. First,
central obesity is one of the present MetS criteria, so
subjects with central obesity wound inevitably have a
higher number of positive MetS components than those
without central obesity if we did not select subjects with
the same number of metabolic abnormalities. We
focused on subjects with only three positive MetS com-
ponents in the present study. No analyses of data for
subjects with four positive components, the maximal
number of abnormalities in the without central obesity
group, were performed because there were fewer cases in
this subgroup. Secondary, as the aim of the present study
was to investigate MetS, we used the criterion of waist
circumference to define central obesity. However, BMI is
often assessed in the study of metabolically obese,
normal-weight (MONW) subjects [35]. In addition, we
did not find significant differences in predicting diabetes
in subjects with normal waist circumference. However,
some adipocytokines, including serum leptin, are asso-
ciated with MetS and insulin resistance in non-obese as
well as obese subjects [39-41]. Further studies on predis-
posing factors leading to diabetes are needed.Conclusions
In Chinese hypertensive families, the incidence of
diabetes in subjects without central obesity was similar
to that in subjects with central obesity when they also
had the same number of positive MetS components. We
suggest that central obesity is very important, but not
the essential component of the metabolic syndrome for
predicting of new-onset diabetes.Abbreviations
BMI: Body mass index; GEE: Generalized estimating equation;
HOMA-IR: Homeostasis model assessment for insulin resistance;
IDF: International Diabetes Federation; MetS: Metabolic syndrome;
MONW: Metabolically obese normal-weight; NCEP: National Cholesterol
Education Program; OGTT: Oral glucose tolerance test; PC: Post-challenge;
SAPPHIRe: Stanford asia-pacific program for hypertension and insulin resistance.Competing interests
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